Compare DexCom, Inc. (DXCM) vs Linde PLC (LIN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
DexCom, Inc. vs Linde PLC — how do they compare? DexCom, Inc. trades at $77.67 (market cap $28.06B), while Linde PLC trades at $516 (market cap $237.72B). The key difference: Linde PLC is far larger — about 8.5× DexCom, Inc.'s market cap, and Linde PLC pays a 1.24% dividend while DexCom, Inc. pays none. Which is the better fit depends on your goals.
| DXCM | LIN | |
|---|---|---|
Market Cap | $28.06B | $237.72B |
Sector | Health | Basic Materials |
52-Week High | $89.53 | $546.64 |
52-Week Low | $54.84 | $389.38 |
Enterprise Value | $27.03B | $260.07B |
Dividend Yield | — | 1.24% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DexCom (DXCM) trades at $74.12, down 2.92% on the day, with a bullish technical signal from moving averages. The company demonstrates strong fundamentals with consistent revenue growth, expanding profit margins, and a track record of beating earnings estimates. Recent regulatory approvals for its G7 15-day CGM in Canada and pediatric clearance for its Stelo OTC system in the U.S. highlight ongoing product expansion.
The investment thesis centers on DexCom's leadership in the growing CGM market, supported by strong financial execution and analyst optimism. Key risks include competition from Abbott, the commercial unproven nature of expansion into non-insulin Type 2 diabetes patients, and potential disruption from GLP-1 drug adoption. The consensus price target of $84.33 suggests ~14% upside from current levels.
Linde (LIN) trades at $522.54, down 0.29% on the day, with a bullish technical signal from moving averages and oversold RSI suggesting potential rebound. The company demonstrates strong fundamentals with consistent earnings beats, including Q1 2026 EPS of $4.33 (beat), and robust profitability with a 20.44% net margin. Recent news highlights sustainability leadership and Q1 results showing 10% EPS growth.
Outlook remains positive given analyst consensus (85.7% buy ratings) and a $560 price target, though high valuation multiples (P/E 34.65) pose a risk if growth moderates. Key risks include rising debt-to-asset ratio (31.63% in 2025) and macroeconomic pressures on industrial demand.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About DexCom, Inc.
Dexcom designs and commercializes continuous glucose monitoring systems for diabetics. CGM systems serve as an alternative to the traditional blood glucose meter process, and the company is evolving its CGM systems to include the disposable sensor and the durable receiver.
Read more on DXCM →About Linde PLC
Linde is the largest industrial gas supplier in the world, with operations in over 100 countries. The firm's main products are atmospheric gases (including oxygen, nitrogen, and argon) and process gases (including hydrogen, carbon dioxide, and helium), as well as equipment used in industrial gas production. Linde serves a wide variety of end markets, including chemicals, manufacturing, healthcare, and steelmaking. Linde generated approximately $31 billion in revenue and $5 billion in GAAP operating profit in 2021.
Read more on LIN →
